Teva Pharma (TEVA) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Piper Jaffray Remains Sidelined on Teva Pharma (TEVA) Following 1Q - PT to $58
May 10, 2016 8:04 AM EDTPiper Jaffray maintained a Neutral rating on Teva Pharma (NYSE: TEVA), and cut the price target to $58.00 (from $59.00), following the company's 1Q earnings report. TEVA reported a non-GAAP EPS of $1.20 on revenues of $4.81B, ahead of the Street's estimates of $1.17 and $4.77B, respectively. Management noted that companies with older, more commodity-focused portfolios should expect... More
Teva Pharma (TEVA) Attractive, Well Managed Business; Price Cut to $75 - Mizuho
May 10, 2016 6:45 AM EDTMizuho analyst, Irina Koffler maintained her Buy rating after Teva Pharma (NYSE: TEVA) effectively defended its generics business and eased concerns about the AGN deal closure. A bottom line beat also helped the stock. We think this is a well-managed business and valuation... More
